Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152211 | 0.94 | ATM (0.36) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL20152173 | 0.89 | GABRP (0.35) | NPC1MAPTRAB9AL3MBTL1MEN1 | |
| SCHEMBL20152218 | 0.88 | MAPT (0.36) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL20152172 | 0.88 | MAPT (0.35) | NPC1LMNAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL18124849 | 0.88 | L3MBTL1 (0.38) | MAPTTLR7L3MBTL1MEN1KMT2A | |
| SCHEMBL19653845 | 0.88 | L3MBTL1 (0.38) | MAPTTLR7L3MBTL1MEN1KMT2A | |
| SCHEMBL19653817 | 0.86 | KDM4E (0.45) | L3MBTL1MEN1KMT2AATM | |
| SCHEMBL10027613 | 0.85 | L3MBTL1 (0.41) | LMNAMAPTADORA3L3MBTL1MEN1 | |
| SCHEMBL21351273 | 0.84 | L3MBTL1 (0.39) | NPC1LMNAMAPTRECQLRAB9A | |
| SCHEMBL19653838 | 0.84 | KDM4E (0.33) | L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662196-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180134718-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2018-05-17 | — | — | US | disclosed |
| US-20180134718-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662196-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, SLCO4C1 | NPC1 214/4885LMNA 2982/4885MAPT 689/4885 |
| US-20180134718-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, SLCO4C1 | NPC1 214/4885LMNA 2982/4885MAPT 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.